| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
CS-866, a novel angiotensin II receptor blocker, is rapidly and completely metabolized to RNH-6270, its active metabolite. The pharmacokinetics of RNH-6270 following oral CS-866 or intravenous RNH-6270 administration was determined in 104 healthy male volunteers. The pharmacokinetics of RNH-6270 was linear over dose ranges of 1 to 32 mg (intravenous RNH-6270 administration) and 10 to 160 mg (oral CS-866 administration). The time to maximum plasma concentration of RNH-6270 after oral CS-866 administration ranged from 1.4 to 2.8 hours, and the terminal elimination half-life ranged from 12 to 18 hours. Absolute bioavailability of RNH-6270 after oral administration of CS-866 was 26%. Administration of CS-866 once daily for 10 days did not result in drug accumulation. When administered intravenously, RNH-6270 has a volume of distribution of 15 to 25 L. Approximately 35% to 50% of RNH-6270 is excreted unchanged in the urine. CS-866 was safe and well tolerated at doses of up to 160 mg/day.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Rohatagi, J. Lee, M. Shenouda, S. Haworth, M. S. Bathala, M. Allison, I. Rubets, R. Heyrman, R. Noveck, and D. E. Salazar Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed-Dose Combination J. Clin. Pharmacol., November 1, 2008; 48(11): 1309 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rohatagi, T. J. Carrothers, S. Kshirsagar, T. Khariton, J. Lee, and D. Salazar Evaluation of Population Pharmacokinetics and Exposure-Response Relationship With Coadministration of Amlodipine Besylate and Olmesartan Medoxomil J. Clin. Pharmacol., July 1, 2008; 48(7): 823 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yamada, K. Maeda, E. Kamiyama, D. Sugiyama, T. Kondo, Y. Shiroyanagi, H. Nakazawa, T. Okano, M. Adachi, J. D. Schuetz, et al. Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor Drug Metab. Dispos., December 1, 2007; 35(12): 2166 - 2176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Iwanaga, M. Sato, T. Maeda, T. Ogihara, and I. Tamai Concentration-Dependent Mode of Interaction of Angiotensin II Receptor Blockers with Uric Acid Transporter J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 211 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Buoen, O. J. Bjerrum, and M. S. Thomsen How First-Time-in-Human Studies Are Being Performed: A Survey of Phase I Dose-Escalation Trials in Healthy Volunteers Published Between 1995 and 2004 J. Clin. Pharmacol., October 1, 2005; 45(10): 1123 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F Gardner and A. M Franks Olmesartan Medoxomil: The Seventh Angiotensin Receptor Antagonist Ann. Pharmacother., January 1, 2003; 37(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
